Food-tech disruptor prepares to vastly scale dairy-identical, non-animal milk protein production in a pioneering sustainable industrial park in Denmark
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Lidocaine and Prilocaine Cream USP, 2.5%/2.5% has an estimated market size of US $ 29 million for twelve months ending Dec. 2021 according to IQVIA
Researchers from the Tel Aviv University successfully engineer the world's first 3D human spinal cord tissue transplant
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Hester's initial pet care portfolio will include products ranging from dermatology, grooming, anti-infective, and speciality products
Subscribe To Our Newsletter & Stay Updated
